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Objectives: This study analyzes the influence of the financial structure of
pharmaceutical companies on R&D investment to create a next-generation profit
source or develop relatively cost-effective drugs to maximize enterprise value.
Methods: The period of the empirical analysis is from 2000 to 2012. Financial
statements and comments in general and internal transactions were extracted
from TS-2000 of the Korea Listed Company Association (KLCA), and data related
to stock price is extracted from KISVALUE-Ⅲ of NICE Information Service Co., Ltd.
Stata 12.0 was used as the statistical package for panel analysis.
Results: The current ratio had a positive influence on R&D investment, the debt
ratio had a negative influence on R&D investment, and return on investment and
net sales growth rate did not have a significant influence on R&D investment.
Conclusion: It was found in this study that the higher liquidity ratio, the greater
the R&D investment. The stability of pharmaceutical companies has a negative
influence on R&D investment. This finding is consistent with the prediction that if
a company faces a financial risk, it will be passive in R&D investment due to its
financial difficulties.1. Introduction
The pharmaceutical industry is likely to suffer a
market failure as it is directly connected to life and health
and its role in limiting the products that are made
available to general consumers. Pharmaceutical com-
panies tend to develop new drugs to treat new diseases
through research and development (R&D) investment to
create a next-generation profit source or developuted under the terms of th
.org/licenses/by-nc-nd/4.0
ginal author and source are
ase Control and Preventionrelatively cost-effective drugs to maximize enterprise
value. R&D in the pharmaceutical industry has the
characteristic of continuously requiring high investments.
Studies that have empirically analyzed R&D investment
in the pharmaceutical industry largely clarify factors that
have positive relevance for R&D investment. Grabowski
and Vernon [1] determined that there is a positive rele-
vance between a firm’s internal cash flow and R&D costs
among pharmaceutical companies. Vernon [2] studiede Creative Commons Attribution-NonCommercial-No Derivative
) which permits non-commercial use, distribution, and repro-
credited.
. Published by Elsevier Korea LLC. All rights reserved.
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and revealed that there is a positive relevance between
the former term’s internal cash flow and the current
term’s expected returns as R&D determinants. Lee and
Lee [3] used explanatory variables such as R&D intensity
and Bank of International Settlements (BIS) ratio, tar-
geting 63 pharmaceutical companies using data from
2001 to 2006, and analyzed their effects on corporate
performance in a time-lag model. They analyzed that
R&D cost intensity a year ago had a positive influence on
the current term’s ratio of ordinary profit but R&D ex-
penditures of 2 years and 3 years previously had a
negative influence on that ratio. This was presumably due
to the research investment characteristics for new drug
developments (long-term investment), and structural
characteristics of R&D activities that focus on incre-
mentally modified drugs and generic medicine.
Many theses in Korea, as well as overseas, emphasize
that internal cash flow can play an important role in a
firm’s actual investment decisions in an imperfect cap-
ital market. R&D investment is not an exception. The
argument that R&D investment can be influenced by
internal finances and internal cash flow originates from
Arrow [4], who stated that high-risk investments such as
technological innovation may face serious “moral haz-
ard” issues and consequently restrict external financing
availability. Moreover, Kamien and Schwartz [5] point
out that internal financing from current profits and
accumulated capital is extremely important for pro-
moting R&D investment. Later, Stiglitz and Weiss [6]
and Myers and Majluf [7] supported Arrow [4] in the
argument that moral hazards and adverse selection is-
sues can be more serious if R&D investment funds are
financed from liabilities and the stock market. Accord-
ing to Modigliani and Miller [8], a firm’s investment
decisions in a perfect capital market are influenced only
by future sales cash flow incurred from investments and
are irrelevant to the capital financing method. However,
the capital market is imperfect and financial factors
intervene in actual investment decisions. Stein [9]
summarized the previous theories concerning reasons
for the increasing importance of financial factors in in-
vestments into two categories.
Firstly, according to the financing constraints hy-
pothesis, there is a cost gap between internal and external
funds due to information asymmetry in the imperfect
capital market, causing a firm’s investment decisions to
be influenced by internal cash flow. Financing constraints
refer to a situation where there are constraints in making
an investment that may have been completed if internal
funds could have been used, but is abandoned due to the
limited availability of external funds or the cost of
external financing [10]. In other words, in such a situation
of financial constraints, internal funds are used first as a
priority for the investment. Therefore, investment ex-
penditures are sensitive to the amount of internal cash
flow. According to the financing constraints hypothesis,the existence of a premium due to information asymmetry
in the external capital market results in the issue of
adverse selection, in which profitable projects are aban-
doned due to high external financing costs [6,7]. In
particular, if other conditions are equal, firms with more
abundant internal cash flow can make necessary in-
vestments smoothly; those without this may underinvest.
Secondly, there is the managerial discretion hypoth-
esis in which the manager uses the firm’s cash flow for
his or her own purposes. If ownership and management
are separated, the manager has the ability to use free
cash flow for opportunistic purposes such as possibly
investing in projects with negative net present value
(NPV < 0) to pursue his or her own interests instead of
returning the free cash flow to shareholders through
dividends. In particular, the manager may use free cash
flow to overinvest due to the appeal of the financial and
nonfinancial benefits achieved through the expansion of
the business scale [11e13]. According to Jensen [11]
and Stulz [13], managers tend to increase controllable
enterprise resources by expanding the business scale
beyond the optimum level if it increases their rewards,
power, and fame. If they can achieve both an increase in
business scale and personal profit, managers may even
implement investment plans with negative NPV
(NPV < 0). In this way, the managerial discretion hy-
pothesis explains how a firm’s investment plans may
respond to the internal financial factor of free cash flow.
Both hypotheses continue to show valid empirical
analysis results, but many cases of R&D investment are
based on the financing constraints hypothesis. This is
because if R&D investment funds are financed from
external financial markets, there is a possibility of a
serious information asymmetry issue [14,15]. The infor-
mation asymmetry issue is especially important in R&D
investment for the following reasons. To begin with,
R&D investment must be supported by both technolog-
ical and market success, thereby having a much higher
risk than real investment; and outside investors face the
information asymmetry issue, feeling greater uncertainty
regarding potential investment success than company
insiders. Next, a firm is likely to promote information
asymmetry or secrecy because if information is provided
to outside investors, it may be exposed to competitors as
well [5,16]. In this case, if the firm’s outside investors
face information asymmetry about R&D investments,
they can demand higher returns above and beyond the
R&D investment funds they provided. Moreover, R&D
investment has weaker mortgage value than real in-
vestments [5,17], resulting in other difficulties in external
financing aside from information asymmetry. Thus, R&D
investment depends largely on internal cash flow due to
the challenges of information asymmetry, as well as
mortgage issues faced with external financing.
As can be seen above, a firm’s R&D investment tends
to depend largely on internal cash flow when there are
issues such as information asymmetry. Moreover, the
304 M. Lee, M. Choiinvestment scale may be influenced by the fluctuation of
internal cash flow, and the R&D investment scale is
adjusted over the long run based on internal cash flow as
the source of funding. Therefore, firms using a mecha-
nism that can stabilize internal cash flow despite low
cash retention can secure continuous financing for R&D
investment. Thus, internal cash flow stabilization re-
lieves the problem of R&D discontinuity or reluctance
so that the investment outcome becomes beneficial in
increasing market concentration or securing long-term
corporate competitiveness, ultimately resulting in a
positive influence on enterprise value.
This study aims to clarify the factors that have a
positive influence on the R&D investment of pharma-
ceutical companies. Specific details are as follows:
 This study analyzes the influence of the financial
structure of pharmaceutical companies on R&D
investment.
 This study evaluates the influential factors identified
through analysis and examines positive promotion
plans.Table 1. Annual distribution of sample firms.
Yr Firms Share Cumulative
2000 39 4.96 4.96
2001 42 5.34 10.31
2002 48 6.11 16.41
2003 51 6.49 22.90
2004 52 6.62 29.52
2005 56 7.12 36.64
2006 58 7.38 44.02
2007 62 7.89 51.91
2008 68 8.65 60.56
2009 72 9.16 69.72
2010 77 9.80 79.52
2011 80 10.18 89.69
2012 81 10.31 100.002. Materials and methods
2.1. Data sources
The period of the empirical analysis was from 2000
to 2012, considering the period after the influence of the
financial crisis. Financial statements and comments in
general and internal transactions were extracted from
TS-2000 of the Korea Listed Company Association
(KLCA), and data related to stock price is extracted
from KISVALUE-Ⅲ of NICE Information Service Co.,
Ltd. Stata 12.0 was used as the statistical package for
panel analysis. Sample firms were those that belong to
the medical substance and drug manufacturing in-
dustries. Cases of complete impairment of capital in the
relevant year and types of management were excluded,
as it may be impossible to compare with other firms and
years due to high risk of bankruptcy. The sample firms
included firms that closed accounts at the end of
December as well as other settling days, but firms that
changed the settling days were excluded as the result
might be distorted due to a short accounting period in
the year in which the day was changed. In analyzing
data on R&D investment, there were issues of omitted
records, inconsistency, and failure of reflected changes
in the database of TS-2000 and KISVALUE-Ⅲ despite
the fact that accuracy of R&D cost-related data was
extremely important. Thus, this study collected data
from the Data Analysis, Retrieval and Transfer System
of the Financial Supervisory Service. Ultimately, 786
firm-year data of 81 firms were included in the sample.
Unbalanced panel data with different data inclusion
periods of variables as in Table 1 could be obtained
according to the availability of data.2.2. Research hypotheses
2.2.1. R&D investment and profitability
A large or increasing profit scale due to high revenues
at a firm indicates that the firm is successful, and induces
the firm to make active R&D investment. Moreover, a
large profit scale and increased profits show that internal
funds can be used for R&D investment. Kamien and
Schwartz [5] argue that the relationship between R&D
investment and net profit differs in intensity depending on
the firm. Venture businesses with high risk finance their
own investments, making high ordinary profit crucial.
This is because securing liquidity from profits generated
by the firm itself can be the direct financing for R&D
investment. This study sets up the following hypothesis to
analyze the influence of the profitability [return on in-
vestment (ROI)] of pharmaceutical companies on R&D
investment based on previous studies.
Hypothesis 1. Profitability (ROI) will have a positive
correlation with R&D.
2.2.2. R&D investment and growth
Firms with higher growth are expected to make more
R&D investments. Pindado et al [18] presented an
analysis result that a firm’s growth and corporate char-
acteristics variables have a positive influence on the
efficiency of the R&D investment. R&D investment and
high growth of the firm increases opportunities for profit
scale expansion, ultimately having a positive effect on
enterprise value. This study sets up the following hy-
pothesis to analyze the influence of the net sales growth
(SG) rate of pharmaceutical companies on R&D in-
vestment based on previous studies.
Hypothesis 2. SG will have a positive correlation with
R&D investment.
2.2.3. R&D investment and liquidity
The theory of financing under information asymme-
try predicts that there is a positive relationship between
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That is, as internal cash flow increases, more external
financial expense can be saved, thereby increasing the
firm’s investment expenditures. Myers and Majluf [7]
stated that when there is information asymmetry and
the manager must represent the interests of the existing
shareholders, he or she tends to preferentially use in-
ternal financing for investment. The existing share-
holders and outsiders share the value increase from
investment if external financing such as liabilities or
rights issue is used for new investment opportunities.
However, if the firm uses internal financing, the increase
in enterprise value is all given to the existing share-
holders. Therefore, the greater the influence of share-
holders on the manager, the greater the possibility of
investment decisions dependent on internal cash flow.
This study sets up the following hypothesis to analyze
the influence of the liquidity level of pharmaceutical
companies on R&D investment based on previous
studies.
Hypothesis 3. Liquidity (LIQ) will have a positive cor-
relation with R&D investment.
2.2.4. (4) R&D investment and stability
R&D investment can be seen as an intangible asset
that contributes to a firm’s future growth. Unlike general
investment in equipment, it has a high risk of failure and
almost no assets to retrieve if it fails. Therefore, banks
are reluctant to invest in R&D, demanding strict con-
ditions or collateral for loans. Thus, firms with extensive
liabilities hesitate to make R&D investments due to the
concern of financial difficulties. In other words, R&D
investment expenditure is, by nature, not an essential
and urgent expenditure, and thus its size will be influ-
enced by the financial position of the firm. Therefore,
firms with high financial risk due to high debt-equity
ratios are expected to be passive in R&D investment.Figure 1. Research model. AD Z advertising; BOD Z size of
SG&A Z selling and administrative expenses.This study sets up the following hypothesis to analyze
the influence of the debt-equity ratio of pharmaceutical
companies on R&D investment based on previous
studies.
Hypothesis 4. Stability (LEV) will have a negative cor-
relation with R&D investment.
2.3. Research model
We applied the research model for the empirical
analysis as follows (Figure 1; Table 2):
RDitZaþ b1ROIit þ b2SGit þ b3LIQit þ b4LEVit
þ b5SIZEit þ b6YEARit þ b7BSit þ b8ADit
þ b9SAEit þ miþ εit
3. Results
3.1. Descriptive statistics
Table 3 shows the descriptive statistics of key vari-
ables of all firms used in the empirical analysis. The
characteristics of probability distribution and the outliers
of key variables are as follows. The dependent variable
of R&D investment appeared to be approximately
6.29%, and the maximum and minimum values show
that there are considerable gaps among firms. The
average of the variables related to financial structure was
lowest in profitability (ROI) with a value of 4.58, while
the average for growth (SG) was 10.73, and that for
stability (LEV) was 67.29. The average of liquidity
(LIQ) was the highest with 361.77, and the maximum
and minimum values show that there are considerable
gaps among firms. Firm size and firm age, which this
study considered as control variables and factors that
may influence R&D investment, turned out not to have athe board of directors; R&D Z research and development;
Table 2. Summary of hypotheses.
Hypotheses
1 Profitability (ROI) will have a positive correlation
with R&D investment.
2 Growth (SG) will have a positive correlation with
R&D investment.
3 Liquidity (LIQ) will have a positive correlation
with R&D investment.
4 Stability (LEV) will have a negative correlation
with R&D investment.
LEV Z stability; LIQ Z liquidity; ROI Z return on investment;
R&D Z research and development; SG Z sales growth.
Table 3. Descriptive statistics.
Variable Obs Mean SD Min Max
RD 786.00 6.29 9.10 0.12 99.07
SIZE 786.00 7.97 0.43 6.98 9.24
YEAR 786.00 1.02 0.43 0.00 1.71
BS 786.00 0.70 0.15 0.00 1.18
AD 786.00 3.53 3.32 0.00 23.32
SAE 786.00 36.33 14.56 3.26 141.77
ROI 786.00 4.58 8.93 63.34 41.50
SG 786.00 10.73 25.31 48.72 501.81
LIQ 786.00 361.77 296.09 35.20 2269.89
LEV 786.00 67.29 91.37 0.00 1549.72
AD Z advertising expense; BS Z business scale; LEV Z stability;
LIQ Z liquidity; Max Z maximum; Min Z minimum;
Obs Z observation; RD Z research and development investment;
SAEZ selling and administrative expenses; SDZ standard deviation;
SG Z sales growth; SIZE Z size of the board of directors;
YEAR Z firm age.
306 M. Lee, M. Choigreat standard deviation compared with the average and,
therefore, appeared not to have a significant problem in
normal distribution.
Table 4 shows a summary of the annual average of
key variables. The trend for these key variables is asTable 4. Annual average of the variables.
Yr RD SIZE YEAR BS AD
2000 2.15 7.87 0.95 0.72 5.08
2001 2.38 7.87 0.96 0.75 5.39
2002 2.93 7.83 0.94 0.71 4.89
2003 3.95 7.84 0.96 0.72 4.26
2004 4.60 7.88 1.00 0.72 3.57
2005 5.50 7.91 1.01 0.69 3.45
2006 5.79 7.94 1.06 0.70 3.63
2007 6.63 7.96 1.04 0.68 3.82
2008 7.00 7.98 1.02 0.71 3.26
2009 7.18 8.02 1.02 0.70 2.96
2010 8.15 8.05 1.04 0.68 2.73
2011 8.45 8.09 1.07 0.69 2.78
2012 10.25 8.11 1.11 0.69 2.49
TOTAL 6.29 7.97 1.02 0.70 3.53
ADZ advertising expense; BSZ business scale; LEVZ stability; LIQZ liq
administrative expenses; SD Z standard deviation; SG Z sales growth; SIZEfollows. The R&D investment variable (RD) is
increasing constantly, while the variables related to
financial structure such as profitability (ROI), growth
(SG), liquidity (LIQ), and stability (LEV) are showing a
downturn since the financial crisis. Variables related to
ownership structure were increasing constantly until the
financial crisis, after which there was a slowdown for a
short time, and then they rose again.
3.2. Correlations
Table 5 presents the Pearson correlation coefficient to
verify the multicollinearity status and correlation among
explanatory variables. In general, the correlation co-
efficients among explanatory variables are not signifi-
cantly high, and thereby the multicollinearity status is
not in doubt. In particular, most correlation coefficients
among explanatory variables appeared to be 0.5 or
below, indicating that there is no multicollinearity
problem. Table 5 shows that certain independent vari-
ables were interrelated and related to the dependent
variables. The following correlations among the
dependent variables and between the dependent vari-
ables and independent variables are significant: RD and
LIQ (0.232) and SAE (0.242) are significantly positively
correlated; RD and ROI (0.167), YEAR (0.210), AD
(0.091) are significantly negatively correlated.
3.3. Regression
This chapter presents the analysis results of
Hypothesis 1, Hypothesis 2, Hypothesis 3, and
Hypothesis 4 that are the focus of this study. To verify
whether there is a positive influence on the relationship
between R&D investment and financial structure,
indices including profitability, growth, liquidity, and
stability were estimated. Table 6 shows the analysis
results of Hypothesis 1, Hypothesis 2, Hypothesis 3, and
Hypothesis 4 estimated by the panel fixed effect model.SAE ROI SG LIQ LEV
36.55 4.85 12.16 282.13 110.60
35.74 8.62 13.55 313.66 124.72
36.03 6.03 10.08 376.72 78.09
37.50 4.71 5.25 404.18 79.78
35.75 5.34 9.52 407.34 58.79
37.71 4.49 11.99 423.39 55.87
38.30 4.22 8.57 431.40 59.29
38.38 4.54 10.98 414.59 55.27
37.17 4.59 19.84 343.75 55.77
36.09 4.63 15.59 340.67 60.24
35.47 4.98 13.58 340.27 56.46
34.29 3.64 5.62 300.05 62.79
34.78 1.77 4.07 342.62 61.37
36.33 4.58 10.73 361.77 67.29
uidity; RDZ research and development investment; SAEZ selling and
Z size of the board of directors; YEAR Z firm age.
Table 5. Pearson’s correlation coefficients.
RD ROI SG LIQ LEV SIZE YEAR BS AD SAE
RD 1
ROI 0.1677* 1
SG 0.0168 0.1218* 1
LIQ 0.2329* 0.1519* 0.0206 1
LEV 0.0567 0.2936* 0.032 0.3012* 1
SIZE 0.0389 0.1020* 0.0328 0.3840* 0.1238* 1
YEAR 0.2109* 0.1734* 0.0942* 0.3208* 0.2156* 0.5650* 1
BS 0.0075 0.0887* 0.0194 0.1823* 0.0482 0.4694* 0.3439* 1
AD 0.0914* 0.0790* 0.0555 0.0967* 0.0518 0.2471* 0.1575* 0.0786* 1
SAE 0.2426* 0.4497* 0.0467 0.0439 0.1129* 0.0728* 0.1075* 0.0034 0.3469* 1
ADZ advertising expense; BSZ business scale; LEVZ stability; LIQZ liquidity; RDZ research and development investment; SAEZ selling and
administrative expenses; SD Z standard deviation; SG Z sales growth; SIZE Z size of the board of directors; YEAR Z firm age. *p < 0.05.
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significant influence on R&D investment. Therefore,
Hypothesis 1 that “ROI will have a positive correlation
with R&D investment” is rejected. Growth (SG) showed
a negative regression coefficient with statistical signifi-
cance. This study measured growth using a net sales
growth rate. Accordingly, it was found that, as sales
increase in comparison to the previous year, R&D in-
vestment decreases. Thus, Hypothesis 2 that a “net sales
growth rate will have a positive correlation with R&D
investment” is rejected. The third hypothesis tests the
positive relationship between current ratio and R&D
investment ratio. In the model, the current ratio and
R&D investment ratio showed a statistically significant
positive relationship. Therefore, the R&D investment
ratio increases if there is more internal cash flow and
liquidity within the firm, which supports Hypothesis 3:
“Liquidity will have a positive correlation with R&D
investment.” Stability (LEV) is a financial ratio that
measures a firm’s stability. If this ratio is low, the firm’s
stability is high, as interest costs due to a firm’s use of
debt are low, thereby enabling the firm to make more
extensive R&D investments. As a result, Hypothesis 4
that the “Stability will have a negative correlation with
R&D investment” is supported.4. Discussion
4.1. Discussion
This study conducted an integrated analysis on the
factors influencing R&D investment in the Korean
pharmaceutical industry, through a detailed review of
the financial structure. To explain the factors influencing
R&D investment in pharmaceutical companies, this
study reviewed previous theories that have been devel-
oped, and then examined the logical basis and validity
concerning the application of the financial structure
theory to pharmaceutical companies. Based on the
above analysis, review, and examination, this study
selected factors that could consummately explain theinfluential factors of R&D investment in pharmaceutical
companies, and then established a hypothesis for each
factor. TS-2000 was used for the analysis data in this
study. The study was conducted in two phases targeting
the ‘medical substance and drug manufacturing in-
dustries’ between 2000 and 2012.
The results showed that: (1) the current ratio had a
positive influence on R&D investment (2) the debt ratio
had a negative influence on R&D investment and (3)
ROI and net sales growth rate did not have a significant
influence on R&D investment. The summary of the
findings and the interpretation of the significance of this
are as follows.
Firstly, it was found in this study that the higher
liquidity ratio, the greater the R&D investment. The
results of this study are similar to the research findings
by Grabowski and Vernon [1], Vernon [2] on pharma-
ceutical companies, as well as research by Kamien and
Schwartz [5], Himmelberg and Petersen [15], Bhagat
and Welch [19] on the manufacturing and financial in-
dustries. The current ratio is an index that determines a
company’s ability to pay short-term debts; a high current
ratio indicates that the company has significant liquidity,
and thus has the ability to generate cash easily. More-
over, greater liquidity implies that the company has the
cash to make active R&D investments. When external
capital markets are unstable, the fluctuations of a com-
pany’s internal finances are likely to affect all compo-
nents of R&D investment. When internal finances
decline, funding-constrained companies will reduce
their accumulation of assets. The degree of this asset
reduction will be influenced by the ease of their dispo-
sition or the size of the adjustment costs.
R&D investment requires relatively high adjustment
costs. Therefore, R&D that requires liquidity will be
restricted when internal finances are reduced, even
though it may be a relatively small amount compared to
the fixed or inventory investment requirements of the
decrement of the total investment. Moreover, as the
company tends not to disclose the elements or progress
of its R&D to the suppliers of external funds, receiving
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308 M. Lee, M. Choiexternal financing will be more difficult and the cost of
such external funds may be higher than internal funds
[16]. This could lead to a phenomenon where the
company prefers internal funds to external funds due to
the asymmetry of information in the loan markets. In
other words, this shows why internal finances have a
significant influence on R&D investment at pharma-
ceutical companies.
Secondly, the stability of pharmaceutical companies
has a negative influence on R&D investment. This
finding is consistent with the prediction that, if a com-
pany faces a financial risk, it will be passive in R&D
investment due to its financial difficulties. This conclu-
sion is similar to the findings of the research by Bay-
singer and Hoskisson [20], Kochhar and David [21],
Hoskisson et al [22]. R&D investment is an intangible
asset that contributes to the future growth of a company,
and strategic decision making is extremely important as
R&D has a high risk of failure, unlike general facilities
investment [17]. It is necessary to examine the ability of
a company to afford external financing, generally
determined by the available financial resources within
the company [21]. In other words, a company’s capital
structure has a significant influence on R&D investment,
and its debt ratio that represents its capital structure
influences its capital financing. Therefore, a company
with high debt ratio will often reduce investment in
R&D due to a concern about potential financial diffi-
culties caused by default, and face detrimental loan
conditions such as high interest rates or onerous security
requirements. Especially in the high-risk pharmaceutical
industry, a company’s financing ability is an important
element, which influences its credit rating. Therefore, if
the internal cash flow of a company deteriorates,
receiving external funding becomes difficult and
financing costs increase. In these circumstances, com-
panies with higher degrees of dependence on short-term
debt face greater difficulties in terms of internal cash
flow. In other words, companies with high debt ratios
may reduce investment in R&D due to concerns about
potential loan defaults and the decrease in their ability to
invest in long-term projects with long payback periods.
4.2. Practical implications
The global pharmaceutical industry is constantly
growing and is expected to grow more in the future in
connection with demand factors, such as an aging so-
ciety and chronic diseases, and supply factors, such as
the expansion of bioresearch. Although the Korean
pharmaceutical industry is also developing, it is ex-
pected that the current structure of this small pharma-
ceutical industry will be greatly adjusted due to
institutional factors such as the Free Trade Agreement.
The key findings and implications of this study are as
follows.
Firstly, according to the results of the analysis
verifying the correlation between financial structure
Determinants of Research and Development Investment in the Pharmaceutical Company Focus on Financial Structures 309and R&D investment, factors that had significant in-
fluence on R&D investment were variables such as
liquidity and stability. The higher the liquidity (and the
lower the stability), the higher was the R&D invest-
ment. In other words, information asymmetry resulted
in liquidity being a more important factor than stabil-
ity. Therefore, it is necessary to develop new drugs
with high initial costs by establishing a public phar-
maceutical company that can easily secure stable
funds. Furthermore, it is necessary to provide support
by selecting companies in each area such as generic,
new drugs, ethical, and over the counter instead of the
top one or two companies supported through the
pharmaceutical fund by the Ministry of Health and
Welfare.
Secondly, there is a need for strategies to develop a
portfolio of products that would improve the compet-
itiveness of the relevant company rather than a
consistent strategy of new drug development. Recently,
many companies consider new drug development as
the only way to secure competitiveness in the tough
conditions prevailing in the pharmaceutical industry.
However, developing new drugs carries great risk,
requiring high investment and time. Therefore, not
only should new drug development be made, but in-
vestment and support should also be provided accord-
ing to the specific factors suitable to improve the
competitiveness of each company, such as generic,
incrementally modified drugs, and biosimilar products.
Furthermore, it is necessary to support the generic in-
dustry, to improve access to drugs. Using generic drugs
to reduce medical costs is a global trend, and consid-
ering the case of Israel’s pharmaceutical company
Teva, as well as India’s policy of developing the
generic industry, fostering the generic industry should
be viewed negatively. Therefore, there is a need for
strategies that are suitable to improve the competi-
tiveness and characteristics of each company.Conflicts of interest
The authors have nothing to disclose.
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